Jun Beom Park

Prof. Jun Beom Park

Chungnam National University Hospital, Daejeon, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2020 in Journal of Minimally Invasive Surgery
Verified
Journal Article
Open access
HKHyun Jeong Ki
Hyun Jeong Ki
JPJun Beom Park
Jun Beom Park
JSJi-Young Sul
Ji-Young Sul
M.M.D.
M.D.
PHPh.D.
Ph.D.
The port site hernia (PSH) is a specific type of incisional hernia related to the trocar sites of laparoscopic surgery. Diastasis recti of the abdominis muscle (DR) is the separation of the rectus muscle by a certain distance. The present study aims to present our experience with umbilical PSH and concomitant DR and to raise awareness of DR as one of the risk factors of umbilical PSH. Eighteen patients with umbilical PSH after laparoscopic abdominal surgery, was retrospectively reviewed. Preoperative CT was analyzed to measure the Inter-recti distance (IRD) for all patients. Other factors, such as trocar size, wound infection, obesity (BMI), port extension, suture materials, and pre-existing co-morbidities, were recorded and analyzed. Extension of the port incision was associated with umbilical PSH. Ten out of eighteen umbilical PSH patients (56%) had DR before they had first laparoscopic surgery. Nine (50%) patients showed sarcopenia. Moreover, four out of five recurrences had DR. More than two recurrences were all associated with DR. Port extension and sarcopenia were risk factors of umbilical PSH. Also, DR might be a possible risk factor of umbilical PSH occurrence and recurrence. Surgeons should be aware of the presence of DR before the planning of the laparoscopic surgery by diagnostic imaging. If DR is associated with umbilical PSH, we need to consider the correction of both pathologies at the same time.

2 November 2022 in Pediatric Gastroenterology, Hepatology & Nutrition
Verified
Journal Article
Open access
PDF file
JCJin Young Cho
Jin Young Cho
MCMea-Young Chang
Mea-Young Chang
MGMi Hyeon Gang
Mi Hyeon Gang
YLYong Wook Lee
Yong Wook Lee
JPJun Beom Park
Jun Beom Park
HKHyun Jin Kim
Hyun Jin Kim
Cho JY, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Nov;25(6):453-460. https://doi.org/10.5223/pghn.2022.25.6.453

1 January 2025 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
HKHyunjeong Ki
Hyunjeong Ki
SKSeyoung Koo
Seyoung Koo
GKGil Ho Kang
Gil Ho Kang
JSJiyoung Sul
Jiyoung Sul
JPJun Beom Park
Jun Beom Park
Ki H, et al. Ann Surg Treat Res. 2025 Apr;108(4):211-218. https://doi.org/10.4174/astr.2025.108.4.211

15 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
HKHyemi Ko
Hyemi Ko
MLMyungsun Lee
Myungsun Lee
ECEunyoung Cha
Eunyoung Cha
JSJiyoung Sul
Jiyoung Sul
JPJun Beom Park
Jun Beom Park
JLjinsun lee
jinsun lee
Background and Objectives; Triple-negative breast cancer (TNBC) is associated with poor patient prognosis because of its multiple molecular features. Thus, more effective treatment for TNBC is urgently needed. This study determined the possible involvement of ERK1/2 activation in cisplatin-induced cytotoxicity in TNBC by providing additional eribulin treatment. Materials and Methods; We investigated cell viability and apoptosis caused by eribulin, cisplatin, or co-treatment in HCC38, MDA-MB-231, and SKBR3 human breast cancer cells. Results; Cisplatin significantly lowered cell viability and caused high apoptotic cell death in all breast cancer cell lines. The viability of TNBC cells was significantly lower in the group co-treated with cisplatin and eribulin than in the cisplatin-only treatment group. Additional eribulin treatment significantly enhanced PARP cleavage and caspase-3 activity in cisplatin-treated TNBC cells. Moreover, cisplatin treatment activated ERK1/2 in all breast cancer cell lines. The cisplatin and eribulin combination synergistically activated ERK1/2 in TNBC cells compared with the cisplatin-only treatment. Administration of the ERK1/2 inhibitor PD98059 increased the viability of TNBC cells treated with cisplatin plus eribulin. Conclusions; Eribulin could synergize the cytotoxic and apoptotic activities of cisplatin and increase ERK1/2 activation, thus enhancing anti-cancer effects against TNBC cells.


1 January 2018 in Advances in Pediatric Surgery
Verified
Journal Article
Open access
PDF file
HJHee-In Jo
Hee-In Jo
JSJi-Young Sul
Ji-Young Sul
JPJun Beom Park
Jun Beom Park
Jo HI, et al. Adv Pediatr Surg. 2018 Dec;24(2):51-59. https://doi.org/10.13029/aps.2018.24.2.51